55094-52-5

Basic information

• Product Name: 2,3,5-Tri-O-benzyl-D-ribonolactone
• Synonyms: 1-Chloro-3,5-di-(p-chlorobenzoyl)-2-deoxy-D-ribofuranose;2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone;2,3,5-TRI-O-BENZYL-D-RIBONOLACTONE;(3R,4R,5R)-3,4-bis(benzyloxy)-5-(benzyloxyMethyl)-dihydrofuran-2(3H)-one;2,3,5-Tris-O-(phenylmethyl)-D-ribonic acid γ-lactone
• CAS NO: 55094-52-5
• Molecular Formula: C₂₆H₂₆O₅
• Molecular Weight: 418.49
• Product Categories: J's
• Mol File: 55094-52-5.mol

Chemical Properties

• Melting Point: 54-55 °C
• Boiling Point: 576.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Sparingly), DMSO (Slightly, Sonicated), Methanol (Slightly)
• CAS DataBase Reference: 2,3,5-Tri-O-benzyl-D-ribonolactone(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,5-Tri-O-benzyl-D-ribonolactone(55094-52-5)
• EPA Substance Registry System: 2,3,5-Tri-O-benzyl-D-ribonolactone(55094-52-5)

Safety Data

• Hazardous Substances Data: 55094-52-5(Hazardous Substances Data)

Usage

Physical Form

Solid

Application

2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a useful research chemical.

Upstream product

• 39085-59-1 trisylhydrazine 
• 89361-52-4 2,3,5-tris-O-(phenylmethyl)-β-D-ribofuranose 
• 16838-89-4 2,3,5-tri-O-benzyl-D-ribofuranose 
• 81927-55-1 O-benzyl 2,2,2-trichloroacetimidate 
• 5336-08-3 D-Ribono-1,4-lactone 
• 74-89-5 methylamine 
• 620946-82-9 (Z)-(2,3,5-tri-O-benzyl-D-ribofuranosylidene)amino methanesulfonate 
• 50-69-1 D-ribose 
• 64363-77-5 methyl 2,3,5-tri-O-benzyl-D-ribofuranoside 
• 1824-96-0 methyl ribofuranoside 
• 100-39-0 benzyl bromide 
• 532-20-7 D-Ribose 
• 7152-47-8 D-ribose diethyl dithioacetal 
• 10257-32-6 D-ribose 

Downstream Products

• 160701-88-2 1-O-Acetyl-2,3,5-tri-O-benzyl-1-(2-thiazolyl)-α-D-ribofuranose 
• 181582-02-5 (3R,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-2-(3,5-dimethoxy-pyrazin-2-yl)-tetrahydro-furan-2-ol 
• 181581-98-6 (3R,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-2-(3,5-dichloro-pyrazin-2-yl)-tetrahydro-furan-2-ol 
• 181582-00-3 (3R,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-2-(5-chloro-3-methoxy-pyrazin-2-yl)-tetrahydro-furan-2-ol 
• 181582-01-4 (3R,4R,5R)-3,4-Bis-benzyloxy-2-(3-benzyloxy-5-chloro-pyrazin-2-yl)-5-benzyloxymethyl-tetrahydro-furan-2-ol 
• 183311-61-7 2-amino-5-(2',3,',5'-tri-O-benzyl-β-D-ribofuranosyl)pyridine 
• 190907-81-4 2-amino-3-methyl-5-(2',3,',5'-tri-O-benzyl-β-D-ribofuranosyl)pyridine 
• 229638-10-2 C₄₆H₄₂N₂O₇ 
• 377777-50-9 5-((2S,3S,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-tetrahydro-furan-2-yl)-[2,2']bipyridinyl 
• 354113-39-6 (3R,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-2-(3,5-dichloro-6-iodo-pyrazin-2-yl)-tetrahydro-furan-2-ol 
• 354113-40-9 (3R,4R,5R)-3,4-Bis-benzyloxy-5-benzyloxymethyl-2-(3,5,6-tris-phenylsulfanyl-pyrazin-2-yl)-tetrahydro-furan-2-ol 

Relevant articles and documents

Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents

The kinetoplastid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases with a serious burden in several parts of the world. These parasites are incapable of synthesizing purines de nov

Compound for treating viral infection and preparation method and application of compound

The invention provides a preparation for treating viral infection and pneumovirus subfamily viral infection, a method, a compound as shown in a formula (I) and a method and intermediate for synthesis of the compound as shown in the formula (I).

Compound containing guanidyl group, and preparation method and application thereof

The invention provides a preparation containing a guanidino compound and used for treating pneumoviridae virus infection, a method, a compound of a formula I, and a method and an intermediate for synthesizing the compound of the formula I.

Novel compound and application thereof

The invention relates to a novel compound and application thereof, and also relates to an application of the compound in preparation of antiviral drugs and the like. In particular, AIDS virus is present. Application of hepatitis B virus, paramyxovirus and

ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME

A new isoform of 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3/4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate (Remdesivir) having increased water solubility is disclosed, along with methods

Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate

Currently, remdesivir is the first and only FDA-approved antiviral drug for COVID-19 treatment. Adequate supplies of remdesivir are highly warranted to cope with this global public health crisis. Herein, we report a Weinreb amide approach for preparing the key intermediate of remdesivir in the glycosylation step where overaddition side reactions are eliminated. Starting from 2,3,5-tri-O-benzyl-d-ribonolactone, the preferred route consisting of three sequential steps (Weinreb amidation, O-TMS protection, and Grignard addition) enables a high-yield (65%) synthesis of this intermediate at a kilogram scale. In particular, the undesirable PhMgCl used in previous methods was successfully replaced by MeMgBr. This approach proved to be suitable for the scalable production of the key remdesivir intermediate.

Method for preparing 2, 3, 5 -tribenzyloxy - D D-ribose -1, 4 - lactone in continuous flow microchannel reactor (by machine translation)

The method disclosed by the invention has the advantages of simple operation, safety, 3 short 5 - reaction time,1 high 4 - product conversion rate, high product purity and the like 2, 3 and 5 - has the advantages of simple operation, 2 safety 3, 5 - short

Preparation method of 2, 3, 5-tribenzyloxy-D-ribose-1, 4-lactone

The invention provides a preparation method of 2, 3, 5-tribenzyloxy-D-ribose-1, 4-lactone. In the preparation method, in the oxidation step, sodium bromide/TEMPO is creatively used as a catalyst, sodium hypochlorite serves as an oxidizing agent, a large a

ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF

Disclosed herein are nucleoside compounds and derivatives thereof, pharmaceutical compositions containing same, and their methods of synthesis. The compounds are useful in treating orthomyxovirus infections, such as influenza infections.

Synthesis of remdesivir key intermediate 2, 3, 5-tribenzyloxy-D-ribotide-1, 4-lactone

The invention relates to synthesis of a remdesivir key intermediate 2, 3, 5-tribenzyloxy-D-ribotide-1, 4-lactone. The invention discloses a synthesis method of 2, 3, 5-tribenzyloxy-D-ribotide-1, 4-lactone, and belongs to the field of organic synthesis. The method includes: taking D-ribose as an initial raw material, in methanol, using concentrated sulfuric acid as a catalyst, synthesizing a methoxy compound 2, then fully stirring the substances in a saturated sodium hydroxide solution, adding tetrahydrofuran and n-butylammonium hydrogen sulfate, and then adding benzyl bromide to synthesize a compound 3, dissolving the compound 3 in tetrahydrofuran and then performing catalysis with concentrated sulfuric acid, and performing reflux stirring overnight treatment to obtain a compound 4, dissolving the compound 4 into dichloromethane and water, adding sodium bicarbonate and TEMPO, slowly adding sodium hypochlorite at 0DEG C, raising the temperature to room temperature, and conducting stirring overnight treatment to obtain a compound 5. The method has the characteristics of easily available raw materials and low production cost, each process step is simple and easy to treat, the yield ofthe whole route reaches 43% or above, industrial production is easy to realize, and a basis is provided for industrialization of remdesivir and subsequent derivatives thereof.